Vadodara News Flash

BK virus infections Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

 Breaking News
  • No posts were found

BK virus infections Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

April 06
16:12 2023
BK virus infections Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies,  Mechanism of Action, Route of Administration by DelveInsight
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, BK virus infections pipeline constitutes key companies continuously working towards developing BK virus infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The BK virus infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

 

BK virus infections Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the BK virus infections Market. 

 

Some of the key takeaways from the BK virus infections Pipeline Report:

  • Companies across the globe are diligently working toward developing novel BK virus infections treatment therapies with a considerable amount of success over the years. 
  • BK virus infections companies working in the treatment market are Orthogon Therapeutics, AiCuris, antibody Memo Therapeutics, SymBio Pharmaceuticals, Vera Therapeutics, AlloVir, and others, are developing therapies for the BK virus infections treatment 
  • Emerging BK virus infections therapies such as – BK virus antiviral therapy, AIC 468, AntiBKV, Brincidofovir, MAU868, ALVR 105, and others are expected to have a significant impact on the BK virus infections market in the coming years.   
  • In March 2021, AlloVir initiated a Phase III study to evaluate ALVR105 (Viralym-M); an allogeneic, of fthe-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus
  • In October 2021, the US Food and drug administration (FDA) granted Orphan Drug Designation (ODD) to posoleucel (ViralymM, ALVR105) for the treatment of virus-associated hemorrhagic cystitis (HC). This Orphan Drug Designation acknowledges theurgent need for new treatment options for patients who have undergone hematopoietic stem cell transplantation and are atrisk for developing viral infections and hemorrhagic cystitis
  • In February 2020, European Medicines Agency (EMA) granted PRIority MEdicines (PRIME) designation to Viralym-M (ALVR105).In March 2020, Viralym-M was granted Orphan Drug Designation from the European Medicines Agency (EMA) as a potential treatment of viral diseases and infections in patients undergoing hematopoietic stem cell transplantation (HSCT).

 

BK virus infections Overview

BK virus (BKV) Infection- The BK virus was first isolated from the urine of a renal transplant recipient with ureteric stenosis in 1971. BK virus is one of 13 known polyomaviruses. Antibodies to BKV are found in approximately 80 to 90 percent of adult’s worldwide, Indicating previous infection or exposure to the virus.

 

Get a Free Sample PDF Report to know more about BK virus infections Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/bk-virus-bkv-infection-pipeline-insight

 

Emerging BK virus infections Drugs Under Different Phases of Clinical Development Include:

  • BK virus antiviral therapy: Orthogon Therapeutics
  • AIC 468: AiCuris
  • AntiBKV: antibody Memo Therapeutics
  • Brincidofovir: SymBio Pharmaceuticals
  • MAU868: Vera Therapeutics
  • ALVR 105: AlloVir
  • Viralym-M: AlloVir

 

Route of Administration

BK virus infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule Type

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

BK virus infections Pipeline Therapeutics Assessment

  • BK virus infections Assessment by Product Type
  • BK virus infections By Stage and Product Type
  • BK virus infections Assessment by Route of Administration
  • BK virus infections By Stage and Route of Administration
  • BK virus infections Assessment by Molecule Type
  • BK virus infections by Stage and Molecule Type

 

DelveInsight’s BK virus infections Report covers around products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further BK virus infections product details are provided in the report. Download the BK virus infections pipeline report to learn more about the emerging BK virus infections therapies

 

BK virus infections Pipeline Analysis:

The BK virus infections pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of BK virus infections with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for BK virus infections Treatment.
  • BK virus infections key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • BK virus infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the BK virus infections market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about BK virus infections drugs and therapies

 

BK virus infections Pipeline Market Drivers

  • Increase in the number of patients requiring kidney transplant worldwide, technological and medical advancements, guidelines supporting early detection and prompt diagnosis are some of the important factors that are fueling the BK virus infections Market.

 

BK virus infections Pipeline Market Barriers

  • However, Lack of effective treatment options against BK virus infection, biology of BKPyV is not completely understood, side effects associated with the current treatment options and other factors are creating obstacles in the BK virus infections Market growth.

 

Scope of BK virus infections Pipeline Drug Insight    

  • Coverage: Global
  • Key BK virus infections Companies: Orthogon Therapeutics, AiCuris, antibody Memo Therapeutics, SymBio Pharmaceuticals, Vera Therapeutics, AlloVir, and others
  • Key BK virus infections Therapies: BK virus antiviral therapy, AIC 468, AntiBKV, Brincidofovir, MAU868, ALVR 105, and others
  • BK virus infections Therapeutic Assessment: BK virus infections current marketed and BK virus infections emerging therapies
  • BK virus infections Market Dynamics: BK virus infections market drivers and BK virus infections market barriers 

 

Request for Sample PDF Report for BK virus infections Pipeline Assessment and clinical trials

 

Table of Contents

1

BK virus infections Report Introduction

2

BK virus infections Executive Summary

3

BK virus infections Overview

4

BK virus infections- Analytical Perspective In-depth Commercial Assessment

5

BK virus infections Pipeline Therapeutics

6

BK virus infections Late Stage Products (Phase II/III)

7

BK virus infections Mid Stage Products (Phase II)

8

BK virus infections Early Stage Products (Phase I)

9

BK virus infections Preclinical Stage Products

10

BK virus infections Therapeutics Assessment

11

BK virus infections Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

BK virus infections Key Companies

14

BK virus infections Key Products

15

BK virus infections Unmet Needs

16 

BK virus infections Market Drivers and Barriers

17

BK virus infections Future Perspectives and Conclusion

18

BK virus infections Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Related Articles